Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc. on October 30, 2023. The filing primarily addresses a corporate action regarding the Company's capital structure rather than operational results for a specific fiscal period.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the mechanics of a reverse stock split.
Material Changes
- Reverse Stock Split: The Company filed an amendment to its Certificate of Incorporation to effectuate a one-for-fifteen (1:15) reverse stock split of its Common Stock.
- Effective Date: The split became effective at 12:01 AM ET on October 31, 2023.
- Share Count Reduction: The number of outstanding shares was reduced from 97,044,838 to approximately 6,466,655 shares.
- Trading Adjustments: Beginning October 31, 2023, the stock trades on The Nasdaq Capital Market under a new CUSIP number (02262M407) on a split-adjusted basis.
- Derivatives Adjustment: All options, warrants, and similar instruments convertible into Common Stock were proportionally adjusted.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future operating results. It includes standard forward-looking statement disclaimers, noting that statements regarding future prospects involve risks and uncertainties that could cause actual results to differ materially from expectations.
Investor Verification Checklist
- Verify the new CUSIP number (02262M407) for trading purposes.
- Confirm the adjusted share count of approximately 6,466,655 shares.
- Review the adjustment terms for any held options or warrants to ensure proportional conversion.
- Check the Company's subsequent filings for updated financial statements reflecting the post-split capitalization.